Header Logo

SAROJ VADHAN

TitleProfessor
InstitutionMD Anderson
DepartmentSarcoma Medical Oncology
Address1515 Holcombe Blvd.
Houston TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL, Tiu RV, Wang X, Callies S, Cox J, Tuttle JL, Lau YK, Roeland EJ. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 03 21; 10(1):73. PMID: 28327200; PMCID: PMC5361694.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    2. Fogelman DR, Morris J, Xiao L, Hassan M, Vadhan S, Overman M, Javle S, Shroff R, Varadhachary G, Wolff R, Vence L, Maitra A, Cleeland C, Wang XS. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer. 2017 06; 25(6):1809-1817. PMID: 28111717.
      Citations: 14     Fields:    Translation:Humans
    3. Vadhan-Raj S, Goldberg JD, Perales MA, Berger DP, van den Brink MR. Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. J Cell Mol Med. 2013 Nov; 17(11):1371-84. PMID: 24251854; PMCID: PMC4117550.
      Citations: 19     Fields:    Translation:HumansAnimals
    4. Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014 Mar; 22(3):679-87. PMID: 24162260.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    5. Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M, National comprehensive cancer network. Myeloid growth factors. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1266-90. PMID: 24142827.
      Citations: 23     Fields:    Translation:Humans
    6. Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, Allen LF. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol. 2014 Jan; 89(1):7-12. PMID: 23983177; PMCID: PMC4223995.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    7. Raj SD, Zhou X, Bueso-Ramos CE, Ravi V, Patel S, Benjamin RS, Vadhan-Raj S. Prognostic significance of elevated D-dimer for survival in patients with sarcoma. Am J Clin Oncol. 2012 Oct; 35(5):462-7. PMID: 21654313.
      Citations: 9     Fields:    Translation:HumansCells
    8. Kanagal-Shamanna R, Zhao W, Vadhan-Raj S, Nguyen MH, Fernandez MH, Medeiros LJ, Bueso-Ramos CE. Over-expression of CYP2E1 mRNA and protein: implications of xenobiotic induced damage in patients with de novo acute myeloid leukemia with inv(16)(p13.1q22); CBF?-MYH11. Int J Environ Res Public Health. 2012 08; 9(8):2788-800. PMID: 23066397; PMCID: PMC3447587.
      Citations: 1     Fields:    Translation:HumansCells
    9. Vadhan-Raj S, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, Henry DH, Novello S, Qian Y, Feng A, Yeh H, Chung K, von Moos R, Hungria V. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol. 2012 Dec; 23(12):3045-3051. PMID: 22851406.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    10. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34. PMID: 22042783; PMCID: PMC3233286.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    11. Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer. 2012 Jun 01; 118(11):2879-88. PMID: 22038701.
      Citations: 31     Fields:    Translation:HumansCells
    12. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5. PMID: 22015451; PMCID: PMC4110463.
      Citations: 21     Fields:    Translation:Humans
    13. Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M, National Comprehensive Cancer Network. Myeloid growth factors. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):914-32. PMID: 21900221.
      Citations: 18     Fields:    Translation:Humans
    14. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011 Mar 20; 29(9):1125-32. PMID: 21343556.
      Citations: 345     Fields:    Translation:HumansCTClinical Trials
    15. Vadhan-Raj S, Zhou X, Sizer K, Lal L, Wang X, Roquemore J, Shi W, Benjamin RS, Lichtiger B. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions. Oncologist. 2010; 15(12):1359-69. PMID: 21159724; PMCID: PMC3227922.
      Citations: 7     Fields:    Translation:Humans
    16. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med. 2010 Oct; 123(10):935-41. PMID: 20920696.
      Citations: 14     Fields:    Translation:Humans
    17. Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 2010 Sep 21; 153(6):358-67. PMID: 20855800.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    18. Vadhan-Raj S. Clinical findings with the first generation of thrombopoietic agents. Semin Hematol. 2010 Jul; 47(3):249-57. PMID: 20620436.
      Citations: 2     Fields:    Translation:HumansCells
    19. Kasyan A, Medeiros LJ, Zuo Z, Santos FP, Ravandi-Kashani F, Miranda R, Vadhan-Raj S, Koeppen H, Bueso-Ramos CE. Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol. 2010 Aug; 23(8):1113-26. PMID: 20473273; PMCID: PMC5846338.
      Citations: 12     Fields:    Translation:HumansCells
    20. Liang M, Han X, Vadhan-Raj S, Nguyen M, Zhang YH, Fernandez M, Drakos E, Konoplev SN, Yin CC, Miranda RN, McDonnell TJ, Medeiros LJ, Bueso-Ramos CE. HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. Mod Pathol. 2010 Mar; 23(3):381-91. PMID: 20062013.
      Citations: 8     Fields:    Translation:HumansCells
    21. Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE. Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer. 2009 Dec 01; 115(23):5481-9. PMID: 19672946; PMCID: PMC3378048.
      Citations: 16     Fields:    Translation:HumansCells
    22. Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, Smith J, Qian Y, Yeh H, Jun S. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol. 2009 Oct; 84(10):650-6. PMID: 19714603.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    23. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009 May; 113(2):210-5. PMID: 19264351; PMCID: PMC4261621.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    24. Park HC, Janjan NA, Mendoza TR, Lin EH, Vadhan-Raj S, Hundal M, Zhang Y, Delclos ME, Crane CH, Das P, Wang XS, Cleeland CS, Krishnan S. Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):775-81. PMID: 19231100; PMCID: PMC3090722.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    25. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol. 2009 Jan; 46(1 Suppl 2):S26-32. PMID: 19245931.
      Citations: 34     Fields:    Translation:Humans
    26. Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK, National Comprehensive Cancer Network. Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83. PMID: 19176207.
      Citations: 13     Fields:    Translation:Humans
    27. Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop. 2009 Mar; 2(1):2-8. PMID: 19669217; PMCID: PMC2713495.
      Citations: 17     
    28. Cella D, Viswanathan HN, Hays RD, Mendoza TR, Stein KD, Pasta DJ, Foreman AJ, Vadhan-Raj S, Kallich JD. Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer. 2008 Sep 15; 113(6):1480-8. PMID: 18642348; PMCID: PMC2587127.
      Citations: 4     Fields:    Translation:Humans
    29. Sun X, Zhang W, Ramdas L, Stivers DN, Jones DM, Kantarjian HM, Estey EH, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE. Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. Mod Pathol. 2007 Aug; 20(8):811-20. PMID: 17571080.
      Citations: 9     Fields:    Translation:HumansCells
    30. Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK, National Comprehensive Cancer Network (NCCN). Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):188-202. PMID: 17335688.
      Citations: 14     Fields:    Translation:Humans
    31. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007 Mar 15; 109(6):2293-302. PMID: 17164350.
      Citations: 141     Fields:    Translation:HumansCells
    32. Zhao W, Claxton DF, Medeiros LJ, Lu D, Vadhan-Raj S, Kantarjian HM, Nguyen MH, Bueso-Ramos CE. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22). Am J Surg Pathol. 2006 Nov; 30(11):1436-44. PMID: 17063086.
      Citations: 2     Fields:    Translation:HumansCells
    33. Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EH. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):762-71. PMID: 17011451.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    34. Johnson MR, Del Carpio-Jayo D, Lin P, Giralt S, Anderlini P, Champlin RE, Khouri IF, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE. Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol. 2006 Oct; 10(5):263-8. PMID: 16979517.
      Citations: 5     Fields:    Translation:HumansCells
    35. Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delcos M, Vadhan SR, Morris J, Ayers GD, Ross A, Brown T, Rodriguez-Bigas MA, Janjan N. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol. 2006 Jun; 29(3):232-9. PMID: 16755175.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    36. 20030125 Study Group Trial, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006 May 20; 24(15):2290-7. PMID: 16710026.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    37. Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenstr?m macroglobulinemia and does not correlate with p65 NF-kappaB activation. Mod Pathol. 2006 Jul; 19(7):891-8. PMID: 16636680.
      Citations: 4     Fields:    Translation:HumansCells
    38. Chaves J, Huen A, Bueso-Ramos C, Safdar A, Vadhan-Raj S. Aerosolized ribavirin-induced reversible hepatotoxicity in a hematopoietic stem cell transplant recipient with Hodgkin lymphoma. Clin Infect Dis. 2006 Apr 15; 42(8):e72-5. PMID: 16575720.
      Citations: 3     Fields:    Translation:Humans
    39. Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK, National Comprehensive Cancer Network. Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul; 3(4):540-55. PMID: 16038645.
      Citations: 4     Fields:    Translation:Humans
    40. Vadhan-Raj S, Cohen V, Bueso-Ramos C. Thrombopoietic growth factors and cytokines. Curr Hematol Rep. 2005 Mar; 4(2):137-44. PMID: 15720963.
      Citations: 7     Fields:    Translation:Humans
    41. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen MH, Aggarwal BB. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004 Feb; 35(2):246-53. PMID: 14991544.
      Citations: 21     Fields:    Translation:Humans
    42. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004 Apr 15; 103(8):3175-84. PMID: 15070700.
      Citations: 122     Fields:    Translation:HumansCells
    43. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, Kavanagh JJ, Hicks ME, Levy LB, Folloder JK, Garcia ME. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res. 2003 Nov 01; 9(14):5228-37. PMID: 14614003.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    44. Vadhan-Raj S, Patel S, Bueso-Ramos C, Folloder J, Papadopolous N, Burgess A, Broemeling LD, Broxmeyer HE, Benjamin RS. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003 Aug 15; 21(16):3158-67. PMID: 12915607.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    45. Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol. 2003 Jul-Aug; 1(2):131-8. PMID: 15352656.
      Citations: 17     Fields:    Translation:Humans
    46. Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, Rivera E, Vadhan-Raj S, Benjamin RS. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer. 2003 Mar 15; 97(6):1541-50. PMID: 12627519.
      Citations: 18     Fields:    Translation:Humans
    47. Vadhan-Raj S. Future directions with hematopoietic growth factors. J Natl Compr Canc Netw. 2003 Jan; 1 Suppl 1:S96-101. PMID: 19795582.
      Citations: 1     Fields:    Translation:Humans
    48. Wautier JL. Safety and usefulness of autologous cryopreserved platelets. Lancet. 2002 Dec 14; 360(9349):1985. PMID: 12493312.
      Citations:    Fields:    Translation:Humans
    49. Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):31-6. PMID: 12435171.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    50. Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, Broemeling LD, Lichtiger B. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet. 2002 Jun 22; 359(9324):2145-52. PMID: 12090979.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    51. Elting LS, Martin CG, Kurtin DJ, Cantor SB, Rubenstein EB, Rodriguez S, Kanesan K, Vadhan-Raj S, Benjamin RS. The Bleeding Risk Index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer. 2002 Jun 15; 94(12):3252-62. PMID: 12115358.
      Citations: 8     Fields:    Translation:Humans
    52. Vadhan-Raj S. Recombinant human thrombopoietin in myelosuppressive chemotherapy. Oncology (Williston Park). 2001 Jul; 15(7 Suppl 8):35-8. PMID: 11497230.
      Citations: 1     Fields:    Translation:Humans
    53. Grazziutti M, Przepiorka D, Rex JH, Braunschweig I, Vadhan-Raj S, Savary CA. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant. 2001 Mar; 27(6):647-52. PMID: 11319596.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    54. Vadhan-Raj S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol. 2000 Apr; 37(2 Suppl 4):28-34. PMID: 10831286.
      Citations: 11     Fields:    Translation:HumansCells
    55. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Freedman RS, Edwards CL, Gershenson D, Jones D, Ashby M, Kavanagh JJ, Kudelk? AP. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000 Mar 07; 132(5):364-8. PMID: 10691586.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    56. Vadhan-Raj S, Currie LM, Bueso-Ramos C, Livesey SA, Connor J. Enhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietin-treated patients following long-term cryopreservation with a platelet-preserving solution (ThromboSol) and 2% DMSO. Br J Haematol. 1999 Feb; 104(2):403-11. PMID: 10050726.
      Citations: 2     Fields:    Translation:HumansCells
    57. Prow D, Vadhan-Raj S. Thrombopoietin: biology and potential clinical applications. Oncology (Williston Park). 1998 Nov; 12(11):1597-604, 1607-8; discussion 1611-4. PMID: 9834938.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    58. Benjapibal M, Kudelka AP, Vasuratna A, Edwards CL, Verschraegen CF, Valero V, Vadhan-Raj S, Kavanagh JJ. Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer. Anticancer Drugs. 1998 Jul; 9(6):577-9. PMID: 9877247.
      Citations: 2     Fields:    Translation:Humans
    59. Vadhan-Raj S. Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol. 1998 Jul; 35(3):261-8. PMID: 9685172.
      Citations: 2     Fields:    Translation:Humans
    60. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998 Jun; 21(3):317-21. PMID: 9626808.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    61. Murray LJ, Luens KM, Estrada MF, Bruno E, Hoffman R, Cohen RL, Ashby MA, Vadhan-Raj S. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis. Exp Hematol. 1998 Mar; 26(3):207-16. PMID: 9502616.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    62. Glisson B, Komaki R, Lee JS, Shin DM, Fossella F, Murphy WK, Kurie J, Perez-Soler R, Schea R, Vadhan-Raj S. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):331-6. PMID: 9457817.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    63. Jones DV, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J, Hellmann S, Fyfe G. Recombinant human thrombopoietin clinical development. Stem Cells. 1998; 16 Suppl 2:199-206. PMID: 11012192.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    64. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol. 1997 Jun; 15(6):2378-84. PMID: 9196153.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    65. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopolous NE, Hittelman WN, Johnston DA, Yang TA, Paton VE, Cohen RL, Hellmann SD, Benjamin RS, Broxmeyer HE. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997 May 01; 126(9):673-81. PMID: 9139552.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    66. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997 Mar; 15(3):1218-34. PMID: 9060566.
      Citations: 74     Fields:    Translation:Humans
    67. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study. J Immunother. 1997 Jan; 20(1):79-87. PMID: 9101417.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    68. Kudelka AP, Termrungruanglert W, Vadhan-Raj S, Edwards CL, Varma DG, Tornos C, Verschraegen CF, Kavanagh JJ. Remission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel. Anticancer Drugs. 1996 Nov; 7(8):885-9. PMID: 8991194.
      Citations:    Fields:    Translation:Humans
    69. Verschraegen CF, Kudelka AP, Termrungruanglert W, de Leon CG, Edwards CL, Freedman RS, Kavanagh JJ, Vadhan-Raj S. Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease. Eur J Cancer. 1996 Aug; 32A(9):1609-11. PMID: 8911126.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    70. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1996 Jun; 14(6):1957-60. PMID: 8656266.
      Citations: 26     Fields:    Translation:Humans
    71. Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996 May; 19(3):206-17. PMID: 8811495.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    72. Ritchie A, Vadhan-Raj S, Broxmeyer HE. Thrombopoietin suppresses apoptosis and behaves as a survival factor for the human growth factor-dependent cell line, M07e. Stem Cells. 1996 May; 14(3):330-6. PMID: 8724699.
      Citations: 4     Fields:    Translation:HumansCells
    73. Vadhan-Raj S. Recombinant human erythropoietin in combination with other hematopoietic cytokines in attenuating chemotherapy-induced multilineage myelosuppression: brief communication. Semin Hematol. 1996 Jan; 33(1 Suppl 1):16-8. PMID: 8714611.
      Citations:    Fields:    Translation:Humans
    74. Broxmeyer HE, Cooper S, Hague N, Benninger L, Sarris A, Cornetta K, Vadhan-Raj S, Hendrie P, Mantel C. Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice. Ann Hematol. 1995 Nov; 71(5):235-46. PMID: 7492626.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    75. Vadhan-Raj S, Broxmeyer HE, Andreeff M, Bandres JC, Buescher ES, Benjamin RS, Papadopoulos NE, Burgess A, Patel S, Plager C, Hittelman WN, McAlister I, Garrison L, Williams DE. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood. 1995 Sep 15; 86(6):2098-105. PMID: 7662957.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    76. Moore DF, Vadhan-Raj S. Sustained response in Felty's syndrome to prolonged administration of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Am J Med. 1995 Jun; 98(6):591-4. PMID: 7778576.
      Citations: 2     Fields:    Translation:Humans
    77. Broxmeyer HE, Benninger L, Cooper S, Hague N, Benjamin RS, Vadhan-Raj S. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma. Exp Hematol. 1995 Apr; 23(4):335-40. PMID: 7895781.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    78. Anaissie EJ, Vadhan-Raj S. Is it time to redefine the management of febrile neutropenia in cancer patients? Am J Med. 1995 Mar; 98(3):221-3. PMID: 7872336.
      Citations: 5     Fields:    Translation:Humans
    79. Vassilopoulou-Sellin R, Kudelka AP, Kavanagh JJ, Edwards CL, Vadhan-Raj S. Effects of interleukin-1 alpha administration on pituitary-adrenal and pituitary-thyroid axes function of patients with ovarian cancer. J Immunother Emphasis Tumor Immunol. 1995 Feb; 17(2):109-13. PMID: 7647956.
      Citations: 1     Fields:    Translation:Humans
    80. Moore DF, Buescher S, Vadhan-Raj S. Interleukin-1 alpha administration increases oral granulocytes and epithelial cells. J Infect Dis. 1994 Jun; 169(6):1419-20. PMID: 8195637.
      Citations:    Fields:    Translation:HumansCells
    81. Vadhan-Raj S. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development. Stem Cells. 1994 May; 12(3):253-61. PMID: 8075592.
      Citations:    Fields:    Translation:HumansAnimalsCells
    82. Vadhan-Raj S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, Arcenas A, Plager C, Kudelka AP, Hittelman WN, et al. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol. 1994 Apr; 12(4):715-24. PMID: 8151315.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    83. Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards CL, Freedman RS, Kavanagh JJ. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol. 1994 Apr; 12(4):707-14. PMID: 8151314.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    84. Broxmeyer HE, Benninger L, Patel SR, Benjamin RS, Vadhan-Raj S. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1994 Jan; 22(1):100-2. PMID: 7506671.
      Citations: 3     Fields:    Translation:HumansCells
    85. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis. 1994; 13 Suppl 2:S18-22. PMID: 7875147.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    86. Buescher ES, McIlheran SM, Banks SM, Vadhan-Raj S. The effects of treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on human polymorphonuclear leukocyte function. Exp Hematol. 1993 Oct; 21(11):1467-72. PMID: 8405227.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    87. Lee AM, Vadhan-Raj S, Hamilton RF, Scheule RK, Holian A. The in vivo effects of rhIL-1 alpha therapy on human monocyte activity. J Leukoc Biol. 1993 Oct; 54(4):314-21. PMID: 8409753.
      Citations: 1     Fields:    Translation:HumansCells
    88. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis. 1993 Oct; 17(4):705-7. PMID: 8268354.
      Citations: 29     Fields:    Translation:HumansCells
    89. Perkins RC, Vadhan-Raj S, Scheule RK, Hamilton R, Holian A. Effects of continuous high dose rhGM-CSF infusion on human monocyte activity. Am J Hematol. 1993 Aug; 43(4):279-85. PMID: 8396850.
      Citations: 4     Fields:    Translation:HumansCells
    90. Buescher ES, McIlheran SM, Banks SM, Kudelka AP, Kavanagh JJ, Vadhan-Raj S. The effects of interleukin-1 therapy on peripheral blood granulocyte function in humans. Cancer Immunol Immunother. 1993 Jul; 37(1):26-30. PMID: 8513450; PMCID: PMC11038441.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    91. Hamilton RF, Vadhan-Raj S, Uthman M, Grey M, Holian A. The in vivo effects of PIXY321 therapy on human monocyte activity. J Leukoc Biol. 1993 Jun; 53(6):640-50. PMID: 8391053.
      Citations: 1     Fields:    Translation:HumansCells
    92. Maze R, Horie M, Hendrie P, Vadhan-Raj S, Tricot G, Gordon M, Nemunaitis J, Ashman LK, Broxmeyer HE. Differential responses of myeloid progenitor cells from patients with myeloid leukemia and myelodysplasia to the costimulating effects of steel factor in vitro. Exp Hematol. 1993 Apr; 21(4):545-51. PMID: 7681784.
      Citations: 1     Fields:    Translation:HumansCells
    93. Arcenas AG, Vadhan-Raj S. Hematopoietic growth factor therapy of myelodysplastic syndromes. Leuk Lymphoma. 1993; 11 Suppl 2:65-9. PMID: 7510197.
      Citations: 1     Fields:    Translation:Humans
    94. Vadhan-Raj S, Broxmeyer HE, Hittelman WN. Use of granulocyte-macrophage colony-stimulating factor in hematopoietic disorders: biology and nature of response. Semin Hematol. 1992 Oct; 29(4 Suppl 3):4-13. PMID: 1492234.
      Citations: 1     Fields:    Translation:HumansAnimalsPHPublic HealthCTClinical Trials
    95. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RW, Holian A, et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol. 1992 Aug; 10(8):1266-77. PMID: 1634916.
      Citations: 15     Fields:    Translation:HumansCells
    96. Broxmeyer HE, Hangoc G, Cooper S, Ribeiro RC, Graves V, Yoder M, Wagner J, Vadhan-Raj S, Benninger L, Rubinstein P, et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A. 1992 May 01; 89(9):4109-13. PMID: 1373894; PMCID: PMC525642.
      Citations: 85     Fields:    Translation:HumansCells
    97. Vadhan-Raj S. Clinical trials of granulocyte-macrophage colony-stimulating factor for the treatment of aplastic anemia. Immunol Ser. 1992; 57:661-70. PMID: 1504150.
      Citations: 1     Fields:    Translation:Humans
    98. Broxmeyer HE, Maze R, Miyazawa K, Carow C, Hendrie PC, Cooper S, Hangoc G, Vadhan-Raj S, Lu L. The kit receptor and its ligand, steel factor, as regulators of hemopoiesis. Cancer Cells. 1991 Dec; 3(12):480-7. PMID: 1726456.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    99. Schilling PJ, Vadhan-Raj S. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia. N Engl J Med. 1990 Sep 20; 323(12):833-4. PMID: 1697401.
      Citations: 8     Fields:    Translation:Humans
    100. Buescher ES, McIlheran SM, Banks SM, Vadhan-Raj S. Alteration of the functional effects of granulocyte-macrophage colony-stimulating factor on polymorphonuclear leukocytes by membrane-fluidizing agents. Infect Immun. 1990 Sep; 58(9):3002-8. PMID: 2167293; PMCID: PMC313602.
      Citations: 1     Fields:    Translation:HumansCells
    101. Ventura GJ, Hester JP, Buescher ES, Vadhan-Raj S, Durrett A, Reading CL. Hematopoiesis in limiting dilution cultures: influence of cytokines on human hematopoietic progenitor cells. Exp Hematol. 1990 Sep; 18(8):878-82. PMID: 2201554.
      Citations:    Fields:    Translation:HumansCells
    102. Gutterman J, Vadhan-Raj S, Logothetis C, Anaissle E, Estey E, Talpaz M, Kurzrock R. Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense. Semin Hematol. 1990 Jul; 27(3 Suppl 3):15-24. PMID: 2198660.
      Citations:    Fields:    Translation:Humans
    103. Hittelman WN, Tigaud JD, Estey E, Vadhan-Raj S. Premature chromosome condensation in the study of minimal residual disease. Bone Marrow Transplant. 1990 Jul; 6 Suppl 1:9-13. PMID: 2202475.
      Citations: 1     Fields:    Translation:HumansCells
    104. Vadhan-Raj S, Hittelman WN, Lepe-Zuniga JL, Gutterman JU, Broxmeyer HE. Regulation of endogenous erythropoietin levels in anemia associated with myelodysplastic syndromes. Blood. 1990 Apr 15; 75(8):1749-50. PMID: 2183890.
      Citations: 3     Fields:    Translation:Humans
    105. Vadhan-Raj S, Velasquez WS, Butler JJ, LeMaistre A, Lepe-Zuniga J, Keating MJ, Koller CA, Gutterman JU. Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte-macrophage colony-stimulating factor. Am J Hematol. 1990 Mar; 33(3):189-97. PMID: 2405649.
      Citations: 1     Fields:    Translation:HumansCells
    106. Vadhan-Raj S, Jeha SS, Buescher S, LeMaistre A, Yee G, Lu L, Lloreta J, Hoots WK, Hittelman WN, Gutterman JU, et al. Stimulation of myelopoiesis in a patient with congenital neutropenia: biology and nature of response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1990 Feb 15; 75(4):858-64. PMID: 2405922.
      Citations: 4     Fields:    Translation:HumansCells
    107. Ventura GJ, Reading CL, Hester JP, Vadhan-Raj S. Circulating myeloid progenitor cell kinetics during hematologic recovery from chemotherapy and subsequent recombinant human granulocyte-macrophage colony-stimulating factor administration. Acta Haematol. 1990; 84(4):175-81. PMID: 2125781.
      Citations: 2     Fields:    Translation:HumansCells
    108. Vadhan-Raj S. Clinical applications of colony-stimulating factors. Oncol Nurs Forum. 1989 Nov-Dec; 16(6 Suppl):21-6. PMID: 2687811.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    109. Vadhan-Raj S, Broxmeyer HE, Spitzer G, LeMaistre A, Hultman S, Ventura G, Tigaud JD, Cork MA, Trujillo JM, Gutterman JU, et al. Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood. 1989 Oct; 74(5):1491-8. PMID: 2676013.
      Citations: 6     Fields:    Translation:Humans
    110. Frenck RW, Buescher ES, Vadhan-Raj S. The effects of recombinant human granulocyte-macrophage colony stimulating factor on in vitro cord blood granulocyte function. Pediatr Res. 1989 Jul; 26(1):43-8. PMID: 2549492.
      Citations: 3     Fields:    Translation:HumansCells
    111. Broxmeyer HE, Cooper S, Vadhan-Raj S. Cell cycle status of erythroid (BFU-E) progenitor cells from the bone marrows of patients on a clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1989 Jun; 17(5):455-9. PMID: 2653858.
      Citations: 2     Fields:    Translation:HumansCells
    112. Ventura GJ, Hester JP, Swan F, Vadhan-Raj S, Turpin J, Dicke KA, Reading CL. Analysis of peripheral blood granulocyte-macrophage colony growth by limiting dilution assay. Exp Hematol. 1989 Feb; 17(2):125-9. PMID: 2643518.
      Citations:    Fields:    Translation:HumansCells
    113. Broxmeyer HE, Vadhan-Raj S. Preclinical and clinical studies with the hematopoietic colony-stimulating factors and related interleukins. Immunol Res. 1989; 8(3):185-201. PMID: 2664033.
      Citations: 5     Fields:    Translation:HumansAnimals
    114. Vadhan-Raj S, Hittelman WN, Broxmeyer HE, Keating M, Urdal D, Gutterman JU. In vivo biologic activities of recombinant human granulocyte-macrophage colony-stimulating factor. Ann N Y Acad Sci. 1989; 554:231-40. PMID: 2660675.
      Citations:    Fields:    Translation:Humans
    115. Vadhan-Raj S, Buescher S, Broxmeyer HE, LeMaistre A, Lepe-Zuniga JL, Ventura G, Jeha S, Horwitz LJ, Trujillo JM, Gillis S, et al. Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1988 Dec 22; 319(25):1628-34. PMID: 3059191.
      Citations: 10     Fields:    Translation:Humans
    116. Buescher ES, McIlheran SM, Vadhan-Raj S. Effects of in vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor on human neutrophil chemotaxis and oxygen metabolism. J Infect Dis. 1988 Nov; 158(5):1140-2. PMID: 3053927.
      Citations:    Fields:    Translation:HumansCells
    117. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol. 1988 Oct; 6(10):1636-48. PMID: 3171629.
      Citations: 17     Fields:    Translation:HumansAnimals
    118. Vadhan-Raj S, Kellagher MJ, Keating M, Walters R, Gutterman JU. Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy. Behring Inst Mitt. 1988 Aug; (83):119-24. PMID: 2467646.
      Citations:    Fields:    Translation:HumansCells
    119. Broxmeyer HE, Cooper S, Williams DE, Hangoc G, Gutterman JU, Vadhan-Raj S. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1988 Aug; 16(7):594-602. PMID: 3260558.
      Citations: 11     Fields:    Translation:HumansCells
    120. Granulocyte-macrophage colony-stimulating factor and myelodysplastic syndromes. N Engl J Med. 1988 Jul 07; 319(1):51-3. PMID: 3288869.
      Citations: 2     Fields:    Translation:Humans
    121. Vadhan-Raj S, Buescher S, LeMaistre A, Keating M, Walters R, Ventura C, Hittelman W, Broxmeyer HE, Gutterman JU. Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1988 Jul; 72(1):134-41. PMID: 3291976.
      Citations: 14     Fields:    Translation:HumansCells
    122. Ince C, Blick M, Lee M, Pathak S, Vadhan-Raj S, Selvanayagam P, Gutterman JU, Cabanillas F. Bcl-1 gene rearrangements in B cell lymphoma. Leukemia. 1988 Jun; 2(6):343-6. PMID: 3259659.
      Citations: 4     Fields:    Translation:HumansCells
    123. Pelus LM, Vadhan-Raj S. Modulation of responsiveness of chronic myelogenous leukemia granulocyte-macrophage colony-forming cells to growth regulation following in vivo treatment with recombinant gamma-interferon. Am J Hematol. 1988 May; 28(1):21-6. PMID: 3130750.
      Citations: 4     Fields:    Translation:HumansCells
    124. Broxmeyer HE, Vadhan-Raj S, Hangoc G, Lu L, Gutterman JU, Williams DE. Preclinical and clinical effects of the hematopoietic colony stimulating factors. Adv Exp Med Biol. 1988; 241:233-41. PMID: 3146907.
      Citations:    Fields:    Translation:HumansAnimals
    125. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987 Dec 17; 317(25):1545-52. PMID: 3500414.
      Citations: 77     Fields:    Translation:Humans
    126. Krown SE, Real FX, Vadhan-Raj S, Oettgen HF. Interferon in AIDS. J Exp Pathol. 1987; 3(4):681-91. PMID: 2457669.
      Citations:    Fields:    Translation:Humans
    127. Vadhan-Raj S, Nathan CF, Sherwin SA, Oettgen HF, Krown SE. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion. Cancer Treat Rep. 1986 May; 70(5):609-14. PMID: 3085930.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    128. Krown SE, Real FX, Vadhan-Raj S, Cunningham-Rundles S, Krim M, Wong G, Oettgen HF. Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer. 1986 Apr 15; 57(8 Suppl):1662-5. PMID: 3081247.
      Citations: 7     Fields:    Translation:HumansCells
    129. Vadhan-Raj S, Al-Katib A, Bhalla R, Pelus L, Nathan CF, Sherwin SA, Oettgen HF, Krown SE. Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol. 1986 Feb; 4(2):137-46. PMID: 3080551.
      Citations: 23     Fields:    Translation:HumansCells
    130. Nathan CF, Horowitz CR, de la Harpe J, Vadhan-Raj S, Sherwin SA, Oettgen HF, Krown SE. Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A. 1985 Dec; 82(24):8686-90. PMID: 3936042; PMCID: PMC391501.
      Citations: 26     Fields:    Translation:HumansCells
    131. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A. 1985 Feb; 82(4):1242-6. PMID: 3883355; PMCID: PMC397231.
      Citations: 91     Fields:    Translation:HumansCTClinical Trials
    132. Effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia. Journal of Community and Supportive Oncology. 14:342-350.
    133. Effects of interleukin-la on ovarian carcinoma in patients with recurrent disease. European Journal of Cancer Part A. 32:1598-1602.
    134. Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. Journal of Translational Medicine. 4.
    135. Hematopoietic growth factors in chemotherapy-induced myelosuppression. Cancer Bulletin. 43:208-214.
    136. Development of the Brief Functional Capacity Tool (BFCT). Journal of Supportive Oncology. 5:10-11.
    137. Erratum. Blood. 122:1325-1326.
    138. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer Journal. 6.
    139. Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. American Journal of Hematology. 91:E3-E5.
    140. Integrating prophylactic measures into practice guidelines. Oncology. 13:593-597.
    141. Mouse monoclonal antibody detecting G(D3) ganglioside.
    142. Evaluation of interleukin-11 (IL-11) in combination with G-CSF administered by different schedules in sarcoma patients receiving adriamycin and ifosfamide (AI) chemotherapy. Blood. 96.
    143. PIXY321 (GM-CSF/IL-3 fusion protein). FORUM - Trends in Experimental and Clinical Medicine. 5:110-118.
    144. Reply to S.M. Sorscher et al. Journal of Clinical Oncology. 29:2736-2737.
    145. Erratum. Clinical Infectious Diseases. 42:1510.
    146. Phenotypic changes induced by recombinant interferon-gamma (r-IFN-γ) therapy in a case of chronic lymphocytic leukemia (CLL).
    147. Expansion of bone marrow progenitors and mobilization of multilineage progenitor cells associated with one-per-cycle administration of the long-acting growth factors pegfilgrastim and darbepoetin alfa with chemotherapy. Journal of Supportive Oncology. 3:22-23.
    148. Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in non-Hodgkin's lymphoma. Journal of Supportive Oncology. 3:24-25.
    VADHAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (510)
    Explore
    _
    Co-Authors (78)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _